SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Class I Drug Recall Notification: Cyclobenzaprine 10 mg
Date: September 2, 2025
Attention: All Providers
Effective date: August 27, 2025
Call to action: Texas Children’s Health Plan (TCHP) would like inform providers that effective August 27, 2025, Unichem Pharmaceuticals (USA), Inc. voluntarily recalled one (1) lot of Cyclobenzaprine Hydrochloride Tablets USP 10 mg to the consumer level. The Cyclobenzaprine 10 mg (90-count) label was inadvertently placed on bottles containing Meloxicam 7.5 mg tablets.
Product affected:
Impacted Medication
NDC No.
Lot No.
Expiration Date
CYCLOBENZAPRINE HYDROCHLORIDE TABELTS USP 10 MG
29300-415-19
GMML24026A
Sept 2027
How this impacts providers: This recall may affect providers whose patients were dispensed the impacted lot, as members may unknowingly be taking Meloxicam instead of Cyclobenzaprine. This could result in ineffective therapy for muscle spasms as well as the potential for adverse effects associated with unintended NSAID use. Providers should be aware that affected patients may contact their offices with questions or concerns and may need counseling regarding discontinuation of the recalled product and appropriate replacement therapy.
Next step for providers: Providers should inform their impacted patients and arrange for the return and replacement of the drug.
